NASDAQ : UNCY
Unicycive Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 104.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 104.18M |
| Enterprise Value | 43.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 27.86M |
| Shares Outstanding | 27.86M |
| Shares Change (YoY) | +107.81% |
| Shares Change (QoQ) | +12.59% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 40.49% |
| Float | 27.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2.45 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 1.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.81 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -571.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -101.07% |
| Return on Assets (ROA) | -40.59% |
| Return on Invested Capital (ROIC) | -58.51% |
| Return on Capital Employed (ROCE) | -62.12% |
| Weighted Average Cost of Capital (WACC) | 14.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.60M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.82 |
| 52-Week Price Change | -22.08% |
| 50-Day Moving Average | 4.54 |
| 200-Day Moving Average | 6.10 |
| Relative Strength Index (RSI) | 40.45 |
| Average Volume (20 Days) | 1,057,600 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.88M |
| Short Previous Month | 4.85M |
| Short % of Shares Out | 17.52% |
| Short % of Float | 17.93% |
| Short Ratio (days to cover) | 5.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.13M |
| Pretax Income | -35.22M |
| Net Income | -35.22M |
| EBITDA | -33.09M |
| EBIT | -33.13M |
| Earnings Per Share (EPS) | -$1.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 61.43M |
| Total Debt | 671,000 |
| Net Cash | 60.75M |
| Net Cash Per Share | $2.18 |
| Equity (Book Value) | 53.27M |
| Book Value Per Share | 1.91 |
| Working Capital | 52.62M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -27.84M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 34,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -27.85M |
| FCF Per Share | -$1.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -107.81% |
| Shareholder Yield | -107.81% |
| Earnings Yield | -41.67% |
| FCF Yield | -26.73% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $28.40 |
| Price Target Difference | 659.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 20, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |